Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,325,419 shares of the biopharmaceutical company's stock after selling 97,963 shares during the quarter. Gilead Sciences makes up approximately 0.7% of Robeco Institutional Asset Management B.V.'s portfolio, making the stock its 25th biggest position. Robeco Institutional Asset Management B.V. owned approximately 0.27% of Gilead Sciences worth $372,613,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Annis Gardner Whiting Capital Advisors LLC grew its holdings in Gilead Sciences by 158.8% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after acquiring an additional 216 shares during the period. Whipplewood Advisors LLC acquired a new position in Gilead Sciences during the fourth quarter worth $35,000. Synergy Investment Management LLC acquired a new position in Gilead Sciences during the fourth quarter worth $40,000. Lee Danner & Bass Inc. acquired a new position in Gilead Sciences during the fourth quarter worth $41,000. Finally, Investment Research & Advisory Group Inc. grew its holdings in Gilead Sciences by 33.3% during the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 100 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences Trading Up 2.8%

NASDAQ GILD traded up $3.05 during mid-day trading on Friday, hitting $110.67. The company's stock had a trading volume of 19,541,254 shares, compared to its average volume of 7,689,778. Gilead Sciences, Inc. has a 52-week low of $66.01 and a 52-week high of $119.96. The stock's fifty day simple moving average is $106.27 and its two-hundred day simple moving average is $103.15. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. The firm has a market capitalization of $137.67 billion, a P/E ratio of 23.30, a price-to-earnings-growth ratio of 0.70 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The firm had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same quarter last year, the firm posted ($1.32) earnings per share. Gilead Sciences's revenue for the quarter was down .3% compared to the same quarter last year. Research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be issued a $0.79 dividend. The ex-dividend date is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.86%. Gilead Sciences's payout ratio is 66.53%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the completion of the sale, the insider now owns 121,152 shares of the company's stock, valued at $13,026,263.04. This trade represents a 18.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $110.17, for a total transaction of $275,425.00. Following the completion of the sale, the chief financial officer now directly owns 165,110 shares of the company's stock, valued at $18,190,168.70. This trade represents a 1.49% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 48,500 shares of company stock worth $5,236,245. Company insiders own 0.27% of the company's stock.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Morgan Stanley upped their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Oppenheimer reduced their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. JPMorgan Chase & Co. upped their price objective on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Finally, Bank of America upped their price objective on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Nine equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences presently has an average rating of "Moderate Buy" and an average price target of $110.55.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.